AGL 40.00 Decreased By ▼ -0.01 (-0.02%)
AIRLINK 127.00 Decreased By ▼ -0.99 (-0.77%)
BOP 6.68 Increased By ▲ 0.08 (1.21%)
CNERGY 4.49 Decreased By ▼ -0.11 (-2.39%)
DCL 8.60 Increased By ▲ 0.12 (1.42%)
DFML 41.30 Decreased By ▼ -0.18 (-0.43%)
DGKC 86.71 Increased By ▲ 0.13 (0.15%)
FCCL 32.16 Increased By ▲ 0.02 (0.06%)
FFBL 64.70 Decreased By ▼ -0.72 (-1.1%)
FFL 10.29 Increased By ▲ 0.04 (0.39%)
HUBC 109.51 Decreased By ▼ -0.98 (-0.89%)
HUMNL 14.90 Increased By ▲ 0.15 (1.02%)
KEL 5.05 Decreased By ▼ -0.08 (-1.56%)
KOSM 7.40 Increased By ▲ 0.28 (3.93%)
MLCF 41.39 Decreased By ▼ -0.26 (-0.62%)
NBP 60.60 Increased By ▲ 0.51 (0.85%)
OGDC 190.00 Decreased By ▼ -4.69 (-2.41%)
PAEL 27.81 Decreased By ▼ -0.14 (-0.5%)
PIBTL 7.75 Decreased By ▼ -0.25 (-3.13%)
PPL 149.75 Decreased By ▼ -1.42 (-0.94%)
PRL 26.73 Decreased By ▼ -0.15 (-0.56%)
PTC 16.18 Increased By ▲ 0.18 (1.13%)
SEARL 86.02 Increased By ▲ 7.82 (10%)
TELE 7.72 Increased By ▲ 0.33 (4.47%)
TOMCL 35.58 Decreased By ▼ -0.09 (-0.25%)
TPLP 8.14 Increased By ▲ 0.23 (2.91%)
TREET 16.51 Increased By ▲ 0.62 (3.9%)
TRG 53.35 Increased By ▲ 0.59 (1.12%)
UNITY 26.28 Decreased By ▼ -0.27 (-1.02%)
WTL 1.26 Decreased By ▼ -0.01 (-0.79%)
BR100 9,889 Decreased By -31.1 (-0.31%)
BR30 30,611 Decreased By -140.9 (-0.46%)
KSE100 93,355 Increased By 130.9 (0.14%)
KSE30 28,931 Increased By 46 (0.16%)
Business & Finance

Novo Nordisk to boost pill-form diabetic drugs with $1.8bn deal

  • The world's biggest producer of diabetes drugs aims to offer more of its current and future drugs in a tablet form.
  • We have been making injection drugs for a hundred years, but we just have to admit that if we want patients to get treatment quickly in order to optimise the long-term course of the illness
Published November 6, 2020

COPENHAGEN: Diabetes drug maker Novo Nordisk said on Friday it had agreed a $1.8 billion deal to acquire Emisphere Technologies, giving it control of a pill technology that it hopes will broaden sales to diabetics with an aversion to shots.

The acquisition comes as Novo's new diabetes pill, Rybelsus - its first-of-a-kind, non-injectable treatment - has been approved by regulators in the United States, Europe and several Asian countries.

The world's biggest producer of diabetes drugs aims to offer more of its current and future drugs in a tablet form.

"I don't think we will ever completely get rid of the needles," Chief Scientific Officer Mads Krogsgaard Thomsen said in an interview.

"We have been making injection drugs for a hundred years, but we just have to admit that if we want patients to get treatment quickly in order to optimise the long-term course of the illness, then it requires tablets if possible," he said.

Under the deal, Novo will buy all outstanding shares in US-based Emisphere for $1.35 billion, while also taking over royalty obligations to the firm's biggest shareholder worth $450 million

Novo said it will make "substantial investments" into the platform and already has around one hundred scientists at its Copenhagen-headquarters working on improving the tablet technology.

"By further developing the technology, we hope in the future to produce the medicine cheaper than we do now, thus allowing us to penetrate more markets and give broader access to diabetes drugs," Thomsen said.

Comments

Comments are closed.